PIM447   Click here for help

GtoPdb Ligand ID: 9790

Synonyms: compound 8 [PMID: 26505898] | LGH-447 | LGH447 | PIM-447
PDB Ligand
Compound class: Synthetic organic
Comment: PIM447 is a potent and selective pan PIM kinase inhibitor [1], that is being investigated for clinical efficacy against hematological malignancies.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 80.9
Molecular weight 440.18
XLogP 4.22
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC1CC(N)CC(C1)c1ccncc1NC(=O)c1ccc(c(n1)c1c(F)cccc1F)F
Isomeric SMILES C[C@@H]1C[C@H](N)C[C@@H](C1)c1ccncc1NC(=O)c1ccc(c(n1)c1c(F)cccc1F)F
InChI InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1
InChI Key VRQXRVAKPDCRCI-ZNMIVQPWSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
A Phase 1 clinical trial evaluating PIM447 in double and triple combinations with ruxolitinib (a JAK1/2 inhibitor) and/or ribociclib (a CDK4/6 inhibitor) in patients with myelofibrosis is underway (see NCT02370706). First-in-human results from patients with relapsed/ refractory multiple myeloma provided proof of principle for PIM kinase inhibition as a novel therapeutic approach in multiple myeloma (Raab et al., May 2019) [2].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
PIM kinases function in the survival, proliferation, and differentiation of hematopoietic cells in response to growth factors and cytokines. All three PIM genes have oncogenic potential, with evidence showing that aberrant PIM expression is implicated in the progression of hematopoietic and solid tumours. Pan-PIM kinase inhibitors are being investigated for antineoplastic activity, as they will combat the functional redundancy of the PIM isoforms.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02370706 Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis Phase 1 Interventional Novartis